Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when MAIA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsMAIA terminates ATM offering after raising $5.7M, ending key capital-raising facility
Filed May 14, 2026 · Period ending May 14, 2026 · ~1 min read
Key Changes
-
medium
MAIA terminated its at-the-market equity offering agreement with H.C. Wainwright effective May 21, 2026, ending a capital-raising facility in place since February 2024.
Item 8.01 view on EDGAR → -
medium
Since March 2025, MAIA sold 3.1 million shares under the ATM for $5.7M in gross proceeds, representing 51% of the up to $11.2M authorized, leaving $5.5M unraised.
Item 8.01 view on EDGAR →
Summary
MAIA Biotechnology closed its at-the-market equity offering facility with H.C. Wainwright on May 14, 2026, with the termination becoming effective seven business days later. The ATM agreement, originally established in February 2024, allowed MAIA to sell shares directly into the market to raise capital as needed.
Under the most recent authorization from March 2025, the company raised approximately $5.7 million by selling 3.1 million shares before shutting down the program. For retail investors, this matters because ATM facilities are a common dilution mechanism for cash-strapped biotechs. The termination could signal either that MAIA has sufficient cash runway or that it plans to pursue alternative financing.
The company left roughly $5.5 million of authorized capacity unused. Watch for MAIA's next quarterly filing to assess cash position and burn rate, which will clarify whether this move reflects financial strength or a strategic pivot to other funding sources.
Section-by-Section Diff
Event · Item 1.02 — Termination of a Material Definitive Agreement
Item 1.02 — Termination of a Material Definitive Agreement filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 14, 2026, MAIA Biotechnology, Inc. (the “Company”) suspended sales of its common stock, par value $0.0001 per share (“Common Stock”), pursuant to that certain At The Market Offering Agreement dated February 14, 2024, or the sales agreement, between the Company and H.C. Wainwright & Co., LLC (the “Agent”), the Company’s sales agent thereunder, and provided notice to the Agent that it is terminating the sales agreement, which termination will be effective 7-business days after May 14, 2026, in accordance with the terms of the sales agreement.
The company terminated its at-the-market equity offering facility with H.C. Wainwright, effective seven business days after May 14, 2026. This ends the company's ability to raise capital through this specific mechanism, which had been in place since February 2024.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 26, 2026 · How we verify